2018
High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana
Nichols JS, Kyriakides TC, Antwi S, Renner L, Lartey M, Seaneke OA, Obeng R, Catlin AC, Gan G, Reynolds NR, Paintsil E, Team O. High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana. AIDS Care 2018, 31: 25-34. PMID: 30235940, PMCID: PMC6288009, DOI: 10.1080/09540121.2018.1524113.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyART adherence ratesPediatric HIV carePrevalence of adherenceAntiretroviral medication adherenceCohort of childrenHIV-positive statusChildren of caregiversChild-caregiver dyadsHIV carePharmacy recordsRefill dataMedian adherenceMedication adherenceAdherence ratesPoor adherenceHigh prevalencePositive statusIntervention studiesHIVGood adherenceAdherenceBaseline dataChildrenTherapy
2012
Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm in the OVER trial
Stroupe KT, Lederle FA, Matsumura JS, Kyriakides TC, Jonk YC, Ge L, Freischlag JA, Group O. Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm in the OVER trial. Journal Of Vascular Surgery 2012, 56: 901-909.e2. PMID: 22640466, DOI: 10.1016/j.jvs.2012.01.086.Peer-Reviewed Original ResearchConceptsTotal health care costsEndovascular repair groupEndovascular groupHealth care providersHealth care costsRepair groupEndovascular repairMean total health care costsCare costsAbdominal aortic aneurysm repairPatient's health care providersVeterans Affairs Cooperative StudyHealth care utilization dataVA Health Economics Resource CenterOpen repair groupAortic aneurysm repairEndovascular AAA repairNon-VA careLength of stayAbdominal aortic aneurysmLower mean costQuality of lifeGraft costsMedicare data sourcesOVER trialPredictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients
Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M. Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients. HIV Medicine 2012, 13: 345-351. PMID: 22276745, DOI: 10.1111/j.1468-1293.2011.00981.x.Peer-Reviewed Original ResearchConceptsCD4 cell countViral load changesWeek 12Replication capacityPredictive valueCell countCD4 cell count responseHIV-1 replication capacityAntiretroviral treatment responseHIV replication capacityImmediate salvage therapyPhenotypic susceptibility scoresDrug-free periodPhenotypic resistance testingCell count responseAdditional predictive valueMultivariate regression analysisTreatment reinitiationSalvage therapyWeek 24ARV therapyViral loadPrognostic valueARV treatmentAntiretroviral trials
2001
Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther support